Studies

24 studies · Download as JSON

• Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and ObesityRandomized trial · 2026 · Study tier 2 · Different population · Mixed · Industry funded
• Retatrutide Once Weekly for Treatment of Obstructive Sleep ApneaRandomized trial · 2026 · Study tier 2 · Different population · Benefit · Industry funded
• Retatrutide treatment in streptozotocin-induced diabetic rats: renal inflammatory cytokines, HIF‑1α expression, and histopathological injury profileAnimal study · 2026 · Study tier 4 · Not human evidence · Mixed
• GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?Narrative review · 2026 · Not rated · Population unclear · Mixed
• Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agentsPharmacovigilance · 2026 · Facts auto-extracted
• Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trialRandomized trial · 2026 · Study tier 2 · Different population · Benefit · Industry funded
• Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of ObesityRandomized trial · 2026 · Study tier 2 · Different population · Benefit · Industry funded
• Future GLP-1 receptor co-agonists and their cardiac effectsAnimal study · 2026 · Facts auto-extracted
• Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoringPharmacovigilance · 2026 · Facts auto-extracted
• Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic ReviewSystematic review · 2026 · Facts auto-extracted
• Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled TrialsMeta-analysis · 2026 · Study tier 2 · Population unclear · Unclear
• Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 DiabetesRandomized trial · 2026 · Study tier 3 · Different population · Mixed · Industry funded
• Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trialRandomized trial · 2026 · Study tier 2 · Different population · Benefit · Industry funded
• Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney diseaseClinical trial · 2026 · Study tier 4 · Different population · Unclear · Industry funded
• Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 DiabetesRandomized trial · 2026 · Study tier 2 · Different population · Benefit
• Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled TrialsMeta-analysis · 2026 · Study tier 2 · Different population · Unclear
• Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 2 · Different population · Mixed
• Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trialsMeta-analysis · 2026 · Study tier 2 · Different population · Harm direction
• Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trialsTrial registration · 2026 · Preliminary · Different population · Unclear · Industry funded
• Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trialsMeta-analysis · 2026 · Facts auto-extracted
• Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipidsRandomized trial · 2025 · Study tier 3 · Not human evidence · Unclear
• Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trialRandomized trial · 2025 · Study tier 2 · Different population · Benefit · Industry funded
• Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled TrialsMeta-analysis · 2025 · Study tier 2 · Different population · Unclear
• Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 TrialRandomized trial · 2023 · Study tier 2 · Different population · Mixed · Industry funded